Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis

Australas J Dermatol. 2011 Aug;52(3):e8-11. doi: 10.1111/j.1440-0960.2010.00660.x. Epub 2010 Jun 23.

Abstract

A 38-year-old woman developed clinical, biochemical, radiological and histopathological evidence of cutaneous and pulmonary sarcoidosis 5 months after commencing adalimumab for chronic plaque psoriasis. Signs and symptoms resolved within 3 months of cessation of adalimumab.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Adult
  • Anti-Inflammatory Agents / adverse effects*
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Female
  • Humans
  • Psoriasis / drug therapy*
  • Sarcoidosis / chemically induced*
  • Sarcoidosis / diagnosis
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • Adalimumab